HRP20120577T1 - 3,4-diarilpirazoli kao inhibitori proteinskih kinaza - Google Patents

3,4-diarilpirazoli kao inhibitori proteinskih kinaza Download PDF

Info

Publication number
HRP20120577T1
HRP20120577T1 HRP20120577AT HRP20120577T HRP20120577T1 HR P20120577 T1 HRP20120577 T1 HR P20120577T1 HR P20120577A T HRP20120577A T HR P20120577AT HR P20120577 T HRP20120577 T HR P20120577T HR P20120577 T1 HRP20120577 T1 HR P20120577T1
Authority
HR
Croatia
Prior art keywords
pyrazol
pyridin
phenyl
optionally substituted
trifluoromethylphenyl
Prior art date
Application number
HRP20120577AT
Other languages
English (en)
Croatian (hr)
Inventor
Pulici Maurizio
Zuccotto Fabio
Badari Alessandra
Nuvoloni Stefano
Cervi Giovanni
Traquandi Gabriella
Biondaro Sonia
Trifiro' Paolo
Marchionni Chiara
Modugno Michele
Original Assignee
Nerviano Medical Sciences S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41059486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120577(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nerviano Medical Sciences S.R.L. filed Critical Nerviano Medical Sciences S.R.L.
Publication of HRP20120577T1 publication Critical patent/HRP20120577T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20120577AT 2008-07-24 2009-07-23 3,4-diarilpirazoli kao inhibitori proteinskih kinaza HRP20120577T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08161076 2008-07-24
PCT/EP2009/059506 WO2010010154A1 (en) 2008-07-24 2009-07-23 3,4-diarylpyrazoles as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
HRP20120577T1 true HRP20120577T1 (hr) 2012-08-31

Family

ID=41059486

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120577AT HRP20120577T1 (hr) 2008-07-24 2009-07-23 3,4-diarilpirazoli kao inhibitori proteinskih kinaza

Country Status (19)

Country Link
US (2) US8541575B2 (enExample)
EP (1) EP2324008B1 (enExample)
JP (1) JP5385382B2 (enExample)
CN (1) CN102105459B (enExample)
AT (1) ATE557015T1 (enExample)
AU (1) AU2009273197B2 (enExample)
BR (1) BRPI0916356B1 (enExample)
CA (1) CA2731146C (enExample)
CL (1) CL2011000124A1 (enExample)
CY (1) CY1117667T1 (enExample)
DK (1) DK2324008T3 (enExample)
EA (1) EA019722B1 (enExample)
ES (1) ES2386408T3 (enExample)
HR (1) HRP20120577T1 (enExample)
MX (1) MX2011000738A (enExample)
PL (1) PL2324008T3 (enExample)
PT (1) PT2324008E (enExample)
SI (1) SI2324008T1 (enExample)
WO (1) WO2010010154A1 (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008001943A1 (es) 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
PT2324008E (pt) * 2008-07-24 2012-06-25 Nerviano Medical Sciences Srl 3,4-diarilpirazoles como inibidores da proteína quinase
JP5603869B2 (ja) 2008-09-29 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
CA2786509C (en) 2010-01-27 2016-01-05 Nerviano Medical Sciences S.R.L. Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
JP5871897B2 (ja) 2010-03-26 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジルトリアゾール
JP5871896B2 (ja) 2010-03-26 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂ−ｒａｆキナーゼインヒビター
AR081810A1 (es) 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
EP2585454A1 (en) * 2010-06-25 2013-05-01 Novartis AG Heteroaryl compounds and compositions as protein kinase inhibitors
WO2012016993A1 (en) 2010-08-03 2012-02-09 Nerviano Medical Sciences S.R.L. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
TWI480276B (zh) * 2010-08-27 2015-04-11 Irm Llc 作為蛋白質激酶抑制劑之化合物及組合物
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
CN103562202B (zh) * 2011-01-25 2016-09-14 密执安大学评议会 Bcl-2/bcl-xl抑制剂和使用它们的治疗方法
CN103403002B (zh) * 2011-02-24 2016-06-22 内尔维阿诺医学科学有限公司 作为激酶抑制剂的噻唑基苯基-苯磺酰氨基衍生物
KR101298651B1 (ko) * 2011-03-16 2013-08-21 연세대학교 산학협력단 효능이 강화된 혈관신생 억제용 약제학적 조성물
WO2013050434A1 (en) 2011-10-06 2013-04-11 Bayer Intellectual Property Gmbh Heterocyclylpyri(mi)dinylpyrazole
CN104039785A (zh) 2011-10-06 2014-09-10 拜耳知识产权有限责任公司 作为杀真菌剂的杂环基吡(嘧)啶基吡唑
US11007194B2 (en) 2011-11-11 2021-05-18 Array Biopharma Inc. Method of treating a proliferative disease
CN105708819B (zh) 2011-11-23 2020-12-29 诺华股份有限公司 医药制剂
ES2625944T3 (es) 2012-11-02 2017-07-21 Pfizer Inc. Inhibidores de tirosina cinasa de Bruton
ES2819232T3 (es) 2013-01-16 2021-04-15 Univ Michigan Regents Inhibidores de Bcl-2/Bcl-xL y su uso en el tratamiento de cáncer
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
ES2918924T3 (es) 2015-04-01 2022-07-21 Rigel Pharmaceuticals Inc Inhibidores de TGF-beta
CN108026050B (zh) * 2015-08-03 2021-04-30 格兰马克药品股份有限公司 作为RORγ调节剂的新型化合物
CN114685516A (zh) 2015-09-16 2022-07-01 洛克索肿瘤学股份有限公司 用于治疗癌症的作为btk抑制剂的吡唑并嘧啶衍生物
EP3390395B1 (en) * 2015-12-16 2020-09-09 Loxo Oncology, Inc. Compounds useful as kinase inhibitors
FI3463345T3 (fi) 2016-06-03 2023-01-31 Farmaseuttisia yhdistelmiä
WO2018051306A1 (en) 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
CN106883266B (zh) * 2017-01-23 2020-03-17 江苏七洲绿色化工股份有限公司 一种1-(4-氯苯基)-2-环丙基-1-丙酮的制备方法及其中间体
EP4272740A1 (en) 2017-05-02 2023-11-08 Novartis AG Combination therapy comprising a raf inhibitor and trametinib
WO2019081477A1 (de) 2017-10-26 2019-05-02 Bayer Cropscience Aktiengesellschaft Substituierte pyrazole sowie deren salze und ihre verwendung als herbizide wirkstoffe
WO2019081485A1 (de) 2017-10-26 2019-05-02 Bayer Cropscience Aktiengesellschaft Substituierte pyrazole sowie deren salze und ihre verwendung als herbizide wirkstoffe
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
JP7186874B2 (ja) * 2018-10-26 2022-12-09 アーリーン ファーマシューティカルズ エルエルシー ピラゾリル化合物およびその使用方法
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
JP2022531969A (ja) 2019-05-13 2022-07-12 ノバルティス アーゲー 癌を治療するためのＲａｆ阻害剤としてのＮ－（３－（２－（２－ヒドロキシエトキシ）－６－モルホリノピリジン－４－イル）－４－メチルフェニル）－２－（トリフルオロメチル）イソニコチンアミドの新規な結晶形態
CA3142286A1 (en) 2019-06-03 2020-12-10 Bayer Aktiengesellschaft 1-phenyl-5-azinyl pyrazolyl-3-oxyalkyl acids and their use for controlling undesired plant growth
CA3150681A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
CN119930611A (zh) 2019-10-11 2025-05-06 因赛特公司 作为cdk2抑制剂的双环胺
KR102323820B1 (ko) * 2019-10-31 2021-11-08 한국화학연구원 돌연변이형 idh 억제제, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
CN112979613B (zh) * 2019-12-16 2022-04-26 四川大学华西医院 2-(1h-吡唑-3-基)吡啶衍生物及其制备方法和用途
WO2021122728A1 (de) 2019-12-19 2021-06-24 Bayer Aktiengesellschaft 1,5-diphenylpyrazolyl-3-oxyalkylsäuren und 1-phenyl-5-thienylpyrazolyl-3-oxyalkylsäuren und deren verwendung zur bekämpfung unerwünschten pflanzenwachstums
WO2021120890A1 (en) * 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents
ES2991524T3 (es) 2020-01-31 2024-12-03 Bayer Ag Derivados del ácido [(1,4,5-trisustituido-1h-pirazol-3-il)sulfanil]acético y sus sales así como su uso como sustancias activas herbicidas
TW202204354A (zh) * 2020-04-02 2022-02-01 美商普雷辛肯公司 用於ｃｓｋ調節之化合物及方法以及其說明
CA3181349A1 (en) 2020-04-29 2021-11-04 Bayer Aktiengesellschaft 1-pyrazinylpyrazolyl-3-oxyalkyl acids and their derivatives, and their use for control of undesired plant growth
EP4161907A1 (en) 2020-06-09 2023-04-12 Array BioPharma Inc. 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders
MX2023004617A (es) 2020-10-23 2023-05-09 Bayer Ag Derivados de 1-(piridil)-5-azinilpirazol y su uso para el combate del crecimiento de plantas no deseado.
AU2021372796A1 (en) * 2020-10-30 2023-06-01 Novartis Ag New crystalline forms of a kras g12c inhibitor compound
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
CA3225190A1 (en) 2021-06-25 2022-12-29 Bayer Aktiengesellschaft (1,4,5-trisubstituted-1h-pyrazole-3-yl)oxy-2-alkoxy alkyl acids and their derivatives, their salts and their use as herbicidal agents
US20250051300A1 (en) * 2021-11-19 2025-02-13 The Board Of Trustees Of The University Of Illinois Gram-negative specific antibiotics sparing effect on gut microbiome
AU2022400175A1 (en) 2021-12-01 2024-07-18 Bayer Aktiengesellschaft (1,4,5-trisubstituted-1h-pyrazole-3-yl)oxy-2-alkoxythio alkyl acids and derivatives thereof, their salts and their use as herbicidal active agents
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2023192801A1 (en) 2022-03-28 2023-10-05 Nikang Therapeutics, Inc. Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
WO2024078871A1 (de) 2022-10-14 2024-04-18 Bayer Aktiengesellschaft 1-pyridyl-5-phenylpyrazolyl-3-oxy- und -3-thioalkylsäuren und derivate und deren verwendung zur bekämpfung unerwünschten pflanzenwachstums

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
NZ501112A (en) 1997-05-22 2002-10-25 G Substituted pyrazoles as p38 kinase inhibitors
US7247734B2 (en) 2001-12-21 2007-07-24 Vernalis (Cambridge) Limited 3,4-diarylpyrazoles and their use in the therapy of cancer
KR20060127032A (ko) * 2004-01-09 2006-12-11 노파르티스 아게 Ｉｇｆ―ｉｒ 억제제로서의페닐-[4-(3-페닐-1ｈ-피라졸-4-일)-피리미딘-2-일]-아민유도체
US20080242667A1 (en) 2005-08-26 2008-10-02 Smithkline Beecham Corporation Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases
WO2007105058A2 (en) * 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
AU2007305016B2 (en) * 2006-10-02 2011-11-03 Novartis Ag Compounds and compositions as protein kinase inhibitors
PT2324008E (pt) * 2008-07-24 2012-06-25 Nerviano Medical Sciences Srl 3,4-diarilpirazoles como inibidores da proteína quinase
CA2786509C (en) * 2010-01-27 2016-01-05 Nerviano Medical Sciences S.R.L. Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
WO2012016993A1 (en) 2010-08-03 2012-02-09 Nerviano Medical Sciences S.R.L. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents

Also Published As

Publication number Publication date
EA201170249A1 (ru) 2011-10-31
AU2009273197B2 (en) 2014-01-16
AU2009273197A2 (en) 2011-03-10
JP2011528698A (ja) 2011-11-24
US20110144068A1 (en) 2011-06-16
CN102105459B (zh) 2014-09-10
EP2324008B1 (en) 2012-05-09
ES2386408T3 (es) 2012-08-20
PL2324008T3 (pl) 2012-09-28
US20140005150A1 (en) 2014-01-02
ATE557015T1 (de) 2012-05-15
BRPI0916356A2 (enExample) 2018-08-21
CL2011000124A1 (es) 2011-05-06
EA019722B1 (ru) 2014-05-30
SI2324008T1 (sl) 2012-08-31
AU2009273197A1 (en) 2010-01-28
CA2731146C (en) 2016-05-03
PT2324008E (pt) 2012-06-25
JP5385382B2 (ja) 2014-01-08
DK2324008T3 (da) 2012-07-23
EP2324008A1 (en) 2011-05-25
US8541575B2 (en) 2013-09-24
BRPI0916356B1 (pt) 2022-08-23
CA2731146A1 (en) 2010-01-28
CN102105459A (zh) 2011-06-22
HK1157337A1 (en) 2012-06-29
MX2011000738A (es) 2011-02-23
CY1117667T1 (el) 2017-05-17
US8946250B2 (en) 2015-02-03
WO2010010154A1 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
HRP20120577T1 (hr) 3,4-diarilpirazoli kao inhibitori proteinskih kinaza
CN100563651C (zh) 具有cb1-拮抗活性的1,3,5-三取代的4,5-二氢-1h-吡唑衍生物
RU2411238C2 (ru) Цис-2,4,5-триарилимидазолины и их применение в качестве противораковых лекарственных средств
RU2475487C2 (ru) Имидазохинолины с иммуномодулирующими свойствами
US9790173B2 (en) Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof-I
US7601868B2 (en) Amine derivative
ES2305317T3 (es) Derivados de amida bifenilcarboxilico como inhibidores de quinasa p38.
RU2004135304A (ru) Производные 2,6-хинолинила и 2,6-нафтила, способы их получения и их применение в качестве ингибиторов vla-4
RU2361868C2 (ru) Новые производные тиазола
RU2003128992A (ru) Омега-аминоалкиламиды r-2-арилпропионовых кислот в качестве ингибиторов хемотаксиса полиморфноядерных и одноядерных клеток
JP2013507449A5 (enExample)
AU2007219509A1 (en) Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
JP4825664B2 (ja) ピペラジン−２−カルボキサミド誘導体
JP2003510319A5 (enExample)
RU2011134052A (ru) Новые бензолсульфонамиды в качестве блокаторов кальциевых каналов
CA2379575A1 (en) Pharmaceutically active sulfonamide derivatives
RU2004100839A (ru) Производные пиперидина полезные в качестве модуляторов активности рецепторов хемокинов
CA2742906A1 (en) Substituted amido phenoxybenzamides
PT1828148E (pt) Compostos de amino benzofenona substituídos por triazol
HRP20161260T1 (hr) Derivati (r)-arilkilamina i farmaceutski pripravci koji ih sadrže
JP6313264B2 (ja) ケイ皮酸アミド誘導体を含有する医薬
US9540338B2 (en) Substituted cinnamic acid amides for treating pain
SK13382003A3 (sk) Derivát kyseliny šťaveľovej, spôsob jeho prípravy, jeho použitie a farmaceutický prostriedok, ktorý ho obsahuje
US11884673B2 (en) Modulators of ion channel receptors and uses thereof
AU2006265997A1 (en) Histamine H3 receptor agents, preparation and therapeutic uses